High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

(2012) Tudor Ciuleanu et al.   LANCET ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non-Small Cell Lung Cancer with T790M Resistance Mutation

(2012) S. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Clinical Significance of Pretreatment C-Reactive Protein in Patients with Advanced Nonsquamous, Non-Small Cell Lung Cancer Who Received Gefitinib

(2011) Katsuhiro Masago et al.   ONCOLOGY

Estimates of cancer incidence and mortality in Europe in 2008

(2010) J. Ferlay et al.   EUROPEAN JOURNAL OF CANCER

Signal Transducer and Activator of Transcription-3, Inflammation, and Cancer

(2009) Bharat B. Aggarwal et al.   Annals of the New York Academy of Sciences

Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas

(2009) J.K. Pine et al.   EJSO

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

(2009) Andrea Koch et al.   Journal of Thoracic Oncology

Serum C-Reactive Protein as Independent Prognostic Variable in Patients with Ovarian Cancer

(2008) L. A. Hefler et al.   CLINICAL CANCER RESEARCH

Role ofKRASandEGFRAs Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21

(2008) Chang-Qi Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer

(2008) Yuhki Koike et al.   JOURNAL OF SURGICAL ONCOLOGY

Cancer-related inflammation

(2008) Alberto Mantovani et al.   NATURE

Correlation of C-Reactive Protein with Survival and Radiographic Response to First-Line Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

(2008) Stefan Wilop et al.   Oncology Research and Treatment